A study on the prevalence, distribution and related factors of heart valve calcification using coronary CT angiography.

Autor:	Kamo Y; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Fujimoto S; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Aoshima C; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Kawaguchi YO; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Nozaki Y; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Kudo A; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Takahashi D; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Takamura K; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Hiki M; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan., Tomizawa N; Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Kumamaru KK; Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Aoki S; Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan., Daida H; Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	International journal of cardiology. Heart & vasculature [Int J Cardiol Heart Vasc] 2020 Jul 01; Vol. 29, pp. 100571. Date of Electronic Publication: 2020 Jul 01 (Print Publication: 2020).
DOI:	10.1016/j.ijcha.2020.100571
Abstrakt:	Background: The concept of active atherosclerotic disease has been accepted for heart valve calcification (HVC). We investigated prevalence, distribution and related factors of HVC in patients who had undergone coronary CT angiography (CCTA). Methods: Subjects were consecutive 200 patients who underwent CCTA. The prevalence and the distribution of HVC using ECG gated non-contrast CT were investigated. Logistic regression analysis and simple regression analysis for factors associated with presence of the calcification and quantitative calcification in the aortic and mitral valve were conducted. Results: HVC was detected in 48.0%. Aortic valve calcification (AVC) was found in 92 cases, the most, followed by mitral valve calcification (MVC) in 25 cases, pulmonary valve in 3 cases, and tricuspid valve in 1 case. Although the left coronary cusp showed the most in 65.2%, no statistic significant difference for Agatston score was detected among each cusp in AVC. Multiple logistic regression analysis showed that age (OR:1.211, 95%C.I.:1.0716-1.1728, p < 0.0001) and coronary artery calcium score (CACS) grade (grade2 OR:7.3393, 95%C.I.:1.7699-30.4349, p = 0.0060, grade3 OR:7.2214, 95%C.I.:1.4376-36.2762, p = 0.0164) were significant factors associated with presence of AVC. The significant factors associated with quantitative AVC were age (p = 0.0043), dyslipidemia (p = 0.0117), and statin use (p = 0.0221). Only age (OR:1.1589, 95%C.I.:1.0726-1.2520, p = 0.0002) was significant factor related to presence of MVC. No significant related factor was found in quantitative MVC. Conclusions: There was an association between presence of AVC and CACS, but not a significant association with presence of MVC. Neither quantitative AVC nor MVC had a significant association with CACS or coronary artery disease. Competing Interests: Dr. Fujimoto has a research agreement with Edwards Lifesciences Ltd. that is related to this study. He also has a research agreement with HeartFlow Japan G.K. and Canon Medical Systems Corporation that is not related to this study. Dr. Aoki has a research agreement with Daiichi-Sankyo Company, Medi-Physics Co., FUJIFILM Toyama Chemical Co. and Bayer Holding Ltd. that is not related to this study. Dr. Daida has received remuneration for lectures from Amgen Astellas Biopharma K.K., Sanofi K.K., Daiichi-Sankyo Pharmaceutical Company Ltd., Terumo Corporation, Boehringer Ingelheim GmbH., Bayer AG., MSD K.K., Mitsubishi Tanabe Parma, Fujifilm, Fuji Chemical Co, Pfizer Pharmaceutical Company Ltd. and Canon Medical Systems Corporation, and research grants from Nihon Medi-Physics Company Ltd., Kowa Pharmaceutical Company Ltd., Daiichi-Sankyo Company Ltd., Canon Medical Systems Corporation, Philips Respironics Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Company Ltd., Sanofi K.K., Boehringer Ingelheim GmbH., Bayer AG., Teijin Ltd., MSD K.K., Pfizer Pharmaceutical Company Ltd., HeartFlow, Novartis Pharma, Nihon Shinyaku, Fujifilm RI Pharm and Actelion Pharmaceuticals Japan Ltd. that is not related to this study. He has been in affiliation with some endowed departments including, Philips Respironics Ltd., Fukuda Denshi Company Ltd. and ResMed Ltd. that is not related to this study. (© 2020 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu